Johnson & Johnson is recalling remnants of about 200,000 syringes of its anemia drug Eprex due to inconsistent potency in dosages.

The erythropeitin replacement treatment is helpful in chronic kidney disease in helping anemic patients cope with the count of low red blood cells.

Because of inconsistent potency in dosages however, the remnants of the drug - just 6,000 remain on the market, are to be recalled across 17 countries, mostly European.

There were no reports of any adverse events, Stefan Gijssels, spokesman for J&J's Janssen Pharmaceuticals division told the Associated Press.

The division reported that US is not affected.

Fewer than 6,300 syringes Eprex remain on the market.